肝臓を標的とする薬剤がマウスの肥満を回復させ、コレステロールを低下させる(Liver-targeting Drug Reverses Obesity, Lowers Cholesterol in Mice)

ad

2023-08-29 マサチューセッツ大学アマースト校

◆マサチューセッツ大学アマースト校の研究者は、自身の研究室で設計されたナノゲルベースのキャリアを使用して、肥満マウスの肝臓にのみ薬を送達し、肥満関連の病気を逆転させる方法を開発しました。
◆この方法により、治療を受けたマウスは体重を完全に減少させ、副作用も見られませんでした。この成果をもとに、この手法を人間に応用するための取り組みが行われており、それに関連して設立されたCyta Therapeutics社は、マサチューセッツ生命科学イノベーション(MALSI)デーで賞を受賞しました。研究者たちは、この方法が将来的に薬として実用化される可能性があるとしています。

<関連情報>

新規ナノ粒子を用いたサイロマイメチンの肝選択性付与が食事誘発性肥満動物モデルにおける治療効果を高める Conferring liver selectivity to a thyromimetic using a novel nanoparticle increases therapeutic efficacy in a diet-induced obesity animal model

Ruiling Wu, Theeraphop Prachyathipsakul, Jiaming Zhuang, Hongxu Liu, Yanhui Han, Bin Liu, Shuai Gong, Jingyi Qiu, Siu Wong, Alexander Ribbe,Jewel Medeiros, Jayashree Bhagabati, Jingjing Gao, Peidong Wu, Ranit Dutta, Roman Herrera, Steve Faraci, Hang Xiao, S Thayumanavan
Proceedings of the National Academy of Sciences NEXUS  Published:29 August 2023
DOI:https://doi.org/10.1093/pnasnexus/pgad252

Preparation of ANG system and profile of specific liver targeting ability in vitro. A) Schematic illustration of the generation of ANG library with tunable particle size and ligand density. ANG with different sizes (N1, N2, N3, and N4) contained the same ligand modification degree (28%). ANG with different ligand modifications (N5, N6, N7, and N8) contained the same size (30 nm). B) Size and ligand modification variations of ANG library confirmed by DLS and UV. C, D) In vitro binding and uptake of the nanogels with different ligand modifications (C) and size (D) to HepG2 cells measured by flow cytometry (left) and corresponding quantification (right). Significant difference between nanogels with different physiochemical parameters was observed. Data are shown as the mean ± SD of n = 3 biologically independent samples. Statistical significance was calculated via two-tailed Student's t-test. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. E) Representative confocal laser scanning microscope images of Cy3–NG (N1, 30 nm, 28% ligand modification) colocalized with actin cytoskeleton (blue, nucleus; red, Cy3-NG; green, actin; scale bar: 100 µm).

Abstract

Optimization of metabolic regulation is a promising solution for many pathologies, including obesity, dyslipidemia, type 2 diabetes, and inflammatory liver disease. Synthetic thyroid hormone mimics–based regulation of metabolic balance in the liver showed promise but was hampered by the low biocompatibility and harmful effects on the extrahepatic axis. In this work, we show that specifically directing the thyromimetic to the liver utilizing a nanogel-based carrier substantially increased therapeutic efficacy in a diet-induced obesity mouse model, evidenced by the near-complete reversal of body weight gain, liver weight and inflammation, and cholesterol levels with no alteration in the thyroxine (T4) / thyroid stimulating hormone (TSH) axis. Mechanistically, the drug acts by binding to thyroid hormone receptor β (TRβ), a ligand-inducible transcription factor that interacts with thyroid hormone response elements and modulates target gene expression. The reverse cholesterol transport (RCT) pathway is specifically implicated in the observed therapeutic effect. Overall, the study demonstrates a unique approach to restoring metabolic regulation impacting obesity and related metabolic dysfunctions.

ad

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました